The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease

BACKGROUND: Recent publications have reported follow-up of the RTS,S/AS01 malaria vaccine candidate Phase III trials at 11 African sites for 32 months (or longer). This includes site- and time-specific estimates of incidence and efficacy against clinical disease with four different vaccination sched...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Malar J
Asıl Yazarlar: Penny, Melissa A., Pemberton-Ross, Peter, Smith, Thomas A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2015
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4634589/
https://ncbi.nlm.nih.gov/pubmed/26537608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12936-015-0969-8
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller